Anemia of Inflammation
Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. It is diagnosed when serum…
Diagnostic Evaluation of Hereditary Hemochromatosis (HFE and Non-HFE)
The management and understanding of hereditary hemochromatosis have evolved with recent advances in iron biology and the associated discovery of numerous genes involved in iron metabolism. HFE -related (type 1)…
Iron Disorders
Matthew M. Heeney, MD, Editor Alan R. Cohen, MD, Editor Ferric (Fe +3 ) iron is ubiquitous in the earth’s environment and an essential metal in the biological processes of…
Waldenström Macrogloblinemia
Waldenström macroglobulinemia (WM) is an IgM-secreting B-cell lymphoproliferative disorder, with strong familial predisposition. MYD88 L265P and CXCR4 WHIM mutations are common in WM and support the growth and survival of…
Novel Targeted Agents in the Treatment of Multiple Myeloma
New, next-generation targeted treatment strategies are required to improve outcomes in patients with multiple myeloma (MM). Monoclonal antibodies, cell signaling inhibitors, and selective therapies targeting the bone marrow microenvironment have…
Immunotherapy Strategies in Multiple Myeloma
Multiple myeloma (MM) is a B-cell malignancy characterized by the clonal proliferation of malignant plasma cells in the bone marrow and the development of osteolytic bone lesions. MM has emerged…
Relapsed and Refractory Multiple Myeloma
New treatment options for patients with myeloma have helped to change the natural history of this disease, even in the context of relapsed disease. For standard-risk patients, doublet-based therapy may…
Allogeneic Stem Cell Transplantation for Multiple Myeloma
Prospective trials comparing tandem autologous stem cell transplantation (ASCT) with ASCT followed by allogeneic stem cell transplantation (AlloSCT) have shown mixed results with regard to progression-free and overall survival rates….
Maintenance Therapy for Multiple Myeloma
Multiple myeloma (MM) is a neoplasm typical of the elderly, with median age at diagnosis of 70 years, and approximately 65% of patients older than 65 years. Many advances have been made…
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
Considerable progress has been recently made in the treatment of elderly patients with multiple myeloma (MM). In Europe the combination of thalidomide with melphalan and prednisone and of bortezomib with…
